Lucid Diagnostics (LUCD) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 09, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-40901
Entity Registrant Name	LUCID DIAGNOSTICS INC.
Entity Central Index Key	0001799011
Entity Tax Identification Number	82-5488042
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	360 Madison Avenue
Entity Address, Address Line Two	25th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	(917)
Local Phone Number	813-1828
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	LUCD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		44,667,304

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 24,050	$ 22,474
Accounts receivable	21	17
Prepaid expenses, deposits, and other current assets	3,232	1,865
Total current assets	27,303	24,356
Fixed assets, net	1,284	1,592
Operating lease right-of-use assets	1,594	2,008
Intangible assets, net	1,929	3,445
Other assets	1,134	1,108
Total assets	33,244	32,509
Current liabilities:
Accounts payable	994	1,056
Accrued expenses and other current liabilities	3,326	1,447
Operating lease liabilities, current portion	1,128	962
Senior Secured Convertible Note - at fair value	14,490
Due To: PAVmed Inc. - MSA Fee and operating expenses	10,286	4,960
Total current liabilities	30,224	8,425
Operating lease liabilities, less current portion	464	1,037
Total liabilities	30,688	9,462
Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.001 par value, 20,000,000 shares authorized; Series A Convertible Preferred Stock, issued and outstanding 13,625 at September 30, 2023 and no shares issued and outstanding at December 31, 2022	13,625
Common stock, $0.001 par value, 200,000,000 shares authorized; 42,329,864 and 40,518,792 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	42	41
Additional paid-in capital	128,800	121,081
Accumulated deficit	(139,911)	(98,075)
Total Stockholders’ Equity	2,556	23,047
Total Liabilities and Stockholders’ Equity	$ 33,244	$ 32,509

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	42,329,864	40,518,792
Common stock, shares outstanding	42,329,864	40,518,792
Series A Preferred Stock [Member]
Preferred stock, shares issued	13,625	0
Preferred stock, shares outstanding	13,625	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 783	$ 76	$ 1,388	$ 265
Operating expenses:
Cost of revenue	1,634	1,626	4,522	1,996
Sales and marketing	3,837	3,930	11,996	11,121
General and administrative	4,320	5,688	15,049	18,465
Amortization of acquired intangible assets	505	505	1,516	1,144
Research and development	1,615	2,704	5,334	8,815
Total operating expenses	11,911	14,453	38,417	41,541
Operating loss	(11,128)	(14,377)	(37,029)	(41,276)
Other income (expense):
Interest income	116	28	330	33
Interest expense	(149)		(405)
Change in fair value - Senior Secured Convertible Note	(3,021)		(3,520)
Loss on issue and offering costs - Senior Secured Convertible Note			(1,186)
Debt extinguishments loss - Senior Secured Convertible Note	(26)		(26)
Other income (expense), net	(3,080)	28	(4,807)	33
Loss before provision for income tax	(14,208)	(14,349)	(41,836)	(41,243)
Provision for income taxes
Net loss	$ (14,208)	$ (14,349)	$ (41,836)	$ (41,243)
Net loss per share - basic	$ (0.34)	$ (0.39)	$ (1.01)	$ (1.15)
Net loss per share - diluted	$ (0.34)	$ (0.39)	$ (1.01)	$ (1.15)
Weighted average common shares outstanding, basic	41,862,805	36,405,945	41,558,979	35,767,857
Weighted average common shares outstanding, diluted	41,862,805	36,405,945	41,558,979	35,767,857

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021		$ 35	$ 96,608	$ (41,904)	$ 54,739
Balance, shares at Dec. 31, 2021		34,917,907
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan			10,371		10,371
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			880		880
Vest - restricted stock awards
Vest - restricted stock awards, shares		169,320
Purchase - Employee Stock Purchase Plan			109		109
Purchase - Employee Stock Purchase Plan, shares		84,030
Net loss				(41,243)	(41,243)
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan		$ 1	693		694
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares		964,716
APA-RDx - Installment Payment			427		427
APA-RDx - Installment Payment, shares		199,989
Issuance - Committed Equity Facility, net of deferred financing charges		$ 1	1,766		1,767
Issuance - Committed Equity Facility, net of deferred financing charges, shares		680,263
CapNostics, LLC			(211)		(211)
Balance at Sep. 30, 2022		$ 37	110,643	(83,147)	27,533
Balance, shares at Sep. 30, 2022		37,016,225
Balance at Jun. 30, 2022		$ 36	105,003	(68,798)	36,241
Balance, shares at Jun. 30, 2022		35,994,667
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan			3,280		3,280
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			291		291
Vest - restricted stock awards
Vest - restricted stock awards, shares		169,320
Purchase - Employee Stock Purchase Plan			109		109
Purchase - Employee Stock Purchase Plan, shares		84,030
Net loss				(14,349)	(14,349)
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan			6		6
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares		5,327
APA-RDx - Installment Payment			188		188
APA-RDx - Installment Payment, shares		82,618
Issuance - Committed Equity Facility, net of deferred financing charges		$ 1	1,766		1,767
Issuance - Committed Equity Facility, net of deferred financing charges, shares		680,263
Balance at Sep. 30, 2022		$ 37	110,643	(83,147)	27,533
Balance, shares at Sep. 30, 2022		37,016,225
Balance at Dec. 31, 2022		$ 41	121,081	(98,075)	23,047
Balance, shares at Dec. 31, 2022		40,518,792
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan			5,014		5,014
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			845		845
Vest - restricted stock awards
Vest - restricted stock awards, shares		303,980
Conversions - Senior Secured Convertible Note			166		166
Conversions - Senior Secured Convertible Note, shares		115,388
Purchase - Employee Stock Purchase Plan			551		551
Purchase - Employee Stock Purchase Plan, shares		508,200
Net loss				(41,836)	(41,836)
APA-RDx - Termination payment			713		713
APA-RDx - Termination payment, shares		553,436
Issuance - At-The-Market Facility, net of deferred financing charges		$ 1	283		284
Issuance - At-The-Market Facility, net of deferred financing charges, shares		230,068
Issuance - Series A Preferred Stock	$ 13,625				13,625
Issuance - Series A Preferred Stock, shares	13,625
Issue common stock - vendor service agreement			147		$ 147
Issue common stock - vendor service agreement, shares		100,000
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares
Balance at Sep. 30, 2023	$ 13,625	$ 42	128,800	(139,911)	$ 2,556
Balance, shares at Sep. 30, 2023	13,625	42,329,864
Balance at Jun. 30, 2023	$ 13,625	$ 42	127,107	(125,703)	15,071
Balance, shares at Jun. 30, 2023	13,625	41,853,603
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan			1,032		1,032
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			220		220
Vest - restricted stock awards
Vest - restricted stock awards, shares		84,660
Conversions - Senior Secured Convertible Note			166		166
Conversions - Senior Secured Convertible Note, shares		115,388
Purchase - Employee Stock Purchase Plan			275		275
Purchase - Employee Stock Purchase Plan, shares		276,213
Net loss				(14,208)	(14,208)
Balance at Sep. 30, 2023	$ 13,625	$ 42	$ 128,800	$ (139,911)	$ 2,556
Balance, shares at Sep. 30, 2023	13,625	42,329,864

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (41,836)	$ (41,243)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	1,870	1,321
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan	5,014	10,371
Stock-based compensation - PAVmed Inc. 2014 Equity Plan	845	880
Change in fair value - Senior Secured Convertible Note	3,520
Loss on issue - Senior Secured Convertible Note	1,111
Debt extinguishment loss - Senior Secured Convertible Note	26
APA-RDx: Issue common stock - settle termination payment	713	427
Issue common stock - vendor service agreement	23
Changes in operating assets and liabilities:
Accounts receivable	(4)	169
Prepaid expenses and other current assets	(1,262)	171
Accounts payable	(62)	(388)
Accrued expenses and other current liabilities	1,878	16
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee	5,326	2,849
Net cash flows used in operating activities	(22,838)	(25,427)
Cash flows from investing activities
Purchase of equipment	(46)	(705)
Asset acquisition		(3,200)
Net cash flows used in investing activities	(46)	(3,905)
Cash flows from financing activities
Proceeds – issue of preferred stock	13,625
Proceeds – issue of Senior Convertible Note	10,000
Proceeds – issue of common stock – Committed Equity Facility		1,807
Proceeds – issue of common stock – At-The-Market Facility	284
Proceeds – exercise of stock options		694
Proceeds – issue common stock – Employee Stock Purchase Plan	551	109
Net cash flows provided by financing activities	24,460	2,610
Net increase (decrease) in cash	1,576	(26,722)
Cash, beginning of period	22,474	53,656
Cash, end of period	$ 24,050	$ 26,934

The Company

The Company	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
The Company	Note 1 — The Company Description of the Business Lucid Diagnostics Inc. (“Lucid”, “Lucid Diagnostics” or the “Company”) is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (“GERD”), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (“EAC”). Lucid is a majority-owned subsidiary of PAVmed Inc. (“PAVmed”). The Company believes that its flagship product, the EsoGuard Esophageal DNA Test, performed on samples collected with the EsoCheck Esophageal Cell Collection Device, constitutes the first and only commercially available diagnostic test capable of serving as a widespread tool for the early detection of esophageal precancer in at-risk GERD patients.. Early detection of esophageal precancer allows patients to undergo appropriate monitoring and treatment, as indicated by clinical practice guidelines, in an effort to prevent progression to esophageal cancer. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Cell samples, including those collected with EsoCheck, as discussed below, are sent to our laboratory, for testing and analyses using our proprietary EsoGuard NGS DNA assay. EsoCheck is a FDA 510(k) and CE Mark cleared noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in a less than a five-minute office procedure. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges, when inflated, to gently swab surface esophageal cells. When vacuum suction is applied, the balloon and sampled cells are pulled into the capsule, protecting them from contamination and dilution by cells outside of the targeted region during device withdrawal. The Company believes that this proprietary Collect+Protect™ technology makes EsoCheck the only noninvasive esophageal cell collection device capable of such anatomically targeted and protected sampling. EsoGuard and EsoCheck are based on patented technology licensed by Lucid from Case Western Reserve University (“CWRU”). EsoGuard and EsoCheck have been developed to provide an accurate, non-invasive, patient-friendly test for the early detection of EAC and Barrett’s Esophagus (“BE”), including dysplastic BE and related pre-cursors to EAC in patients with chronic GERD. Liquidity The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company expects to continue to experience recurring losses from operations and will continue to fund its operations with debt and equity financing transactions, including current obligations on the Company’s existing convertible debt which in accordance with management’s plans may include conversions to equity and refinancing our existing debt obligations to extend the maturity date. Notwithstanding, however, with the cash on-hand as of the date hereof and committed equity sources of financing, conversion and refinancing of existing convertible notes, the Company expects to be able to fund its operations and meet its financial obligations as they become due for the one year period from the date of the issue of the Company’s unaudited condensed consolidated financial statements, as included herein in this Quarterly Report on Form 10-Q for the period ended September 30, 2023.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Significant Accounting Policies The Company’s significant accounting policies are as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 14, 2023, except as otherwise noted herein below. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company is a majority-owned consolidated subsidiary of PAVmed, which has a majority equity ownership interest and has financial control of the Company. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2022 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company’s unaudited condensed consolidated financial information. The consolidated results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2023 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company’s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K as filed with the SEC on March 14, 2023. All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts. Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserves, if any, and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards and intangible assets. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Note 2 — Summary of Significant Accounting Policies The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Allocate transaction price Practical Expedients Financial Instruments Fair Value Measurements FASB ASC Topic 820, Fair Value Measurement, (ASC 820) defines fair value as the price which would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at a transaction measurement date. The ASC 820 three-tier fair value hierarchy prioritizes the inputs used in the valuation methodologies, as follows: Level Valuations based on quoted prices for identical assets and liabilities in active markets. Level Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets which are not active, or other inputs observable or can be corroborated by observable market data. Level 3 Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company evaluates its financial instruments to determine if those instruments or any embedded components of those instruments potentially qualify as derivatives required to be separately accounted for in accordance with FASB ASC Topic 815, Derivatives and Hedging (ASC 815). Note 2 — Summary of Significant Accounting Policies The recurring and non-recurring estimated fair value measurements are subjective and are affected by changes in inputs to the valuation models, including the Company’s common stock price, and certain Level 3 inputs, including, the assumptions regarding the estimated volatility in the value of the Company’s common stock price; the Company’s dividend yield; the likelihood and timing of future dilutive transactions, as applicable, along with the risk-free rates based on U.S. Treasury security yields. Changes in these assumptions can materially affect the estimated fair values. As of September 30, 2023 and December 31, 2022, the carrying values of cash, and accounts payable, approximate their respective fair value due to the short-term nature of these financial instruments. Fair Value Option (“FVO”) Election Under a Securities Purchase Agreement dated March 13, 2023, the Company issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “March 2023 Senior Convertible Note”, which is accounted under the “fair value option election” as discussed below. Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivative and Hedging Alternatively, FASB ASC Topic 825, Financial Instruments See Note 10, Financial Instruments Fair Value Measurements, with respect to the FVO election; and Note 11, Debt, for a discussion of the March 2023 Senior Convertible Note. Reclassifications Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The updated guidance requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets, including trade receivables. The guidance was adopted by the Company on January 1, 2023. The adoption of the ASU did not have an impact on the Company’s unaudited condensed consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Note 3 — Revenue from Contracts with Customers EsoGuard Commercialization Agreement The Company entered into the EsoGuard Commercialization Agreement, dated August 1, 2021, with its former commercial laboratory service provider, ResearchDx Inc. (“RDx”), an unrelated third-party. The EsoGuard Commercialization Agreement was on a month-to-month basis and was terminated on February 25, 2022 upon the execution of an asset purchase agreement (“APA”) dated February 25, 2022, between LucidDx Labs Inc., a wholly-owned subsidiary of the Company, and RDx, with such agreement further discussed in Note 6, Asset Purchase Agreement and Management Services Agreement Note 3 — Revenue from Contracts with Customers Revenue Recognized In the three and nine months ended September 30, 2023, the Company recognized revenue of $ 783 1,388 76 265 100 Cost of Revenue The cost of revenues principally includes the costs related to the Company’s laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties. In the three and nine months ended September 30, 2023, the cost of revenue was $ 1,634 4,522 1,626 1,996

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 — Related Party Transactions Case Western Reserve University and Physician Inventors - Amended CWRU License Agreement Case Western Reserve University (“CWRU”) and each of the three physician inventors (“Physician Inventors”) of the intellectual property licensed under the amended and restated patent license agreement with CWRU, dated August 23, 2021 (the “Amended CWRU License Agreement”), each hold a minority equity ownership interest in Lucid Diagnostics Inc. The expenses incurred with respect to the Amended CWRU License Agreement and the three Physician Inventors, as classified in the accompanying unaudited condensed consolidated statement of operations for the periods indicated are summarized as follows: Schedule of Incurred Expenses of Minority Shareholders 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of Revenue CWRU – Royalty Fees $ 42 $ 4 $ 76 $ 13 General and Administrative Expense Amended CWRU – License Agreement - reimbursement of patent legal fees 343 — 732 209 Stock-based compensation expense – Physician Inventors’ restricted stock awards — 275 180 819 Research and Development Expense Fees - Physician Inventors’ consulting agreements 5 15 15 32 Sponsored research agreement — 4 — 6 Stock-based compensation expense – Physician Inventors’ stock options 52 52 157 151 Total Related Party Expenses $ 442 $ 350 $ 1,160 $ 1,230 As of September 30, 2023, the Company had an outstanding payable of $ 820 Note 4 — Related Party Transactions PAVmed Inc. - Management Services Agreement The Company’s daily operations are also managed in part by personnel employed by PAVmed, for which the Company incurs a service fee, referred to as the “MSA Fee”, according to the provisions of a Management Services Agreement (“MSA”) with PAVmed. The MSA does not have a termination date, but may be terminated by the Company’s board of directors. The MSA Fee is charged on a monthly basis and is subject-to periodic adjustment corresponding with changes in the services provided by PAVmed personnel to the Company, with any such change in the MSA Fee being subject to approval of the boards of directors of each of the Company and PAVmed. The respective companies’ boards of directors approved a seventh amendment to the MSA to increase the MSA Fee to $ 750 550 390 The MSA Fee expense classification in the unaudited condensed consolidated statement of operations for the periods noted is as follows: Schedule of MSA Fee Expense Classification in Statements of Operations 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Sales & Marketing 109 330 327 713 General & Administrative 1,621 891 4,729 2,175 Research & Development 520 429 1,694 1,102 Total MSA Fee $ 2,250 $ 1,650 $ 6,750 $ 3,990 The classification of the MSA Fee as presented above is based on the PAVmed classification of employee salary expense and other operating expenses. In this regard, PAVmed classifies employee salary expense as sales and marketing expenses for employees performing sales, marketing, and reimbursement activities and functions, general and administrative, and research and development except for those employees who are engaged in product and services engineering development and design and /or clinical trials activities, for which such employee salary is classified as research and development expense.

Due To PAVmed Inc.

Due To PAVmed Inc.	9 Months Ended
	Sep. 30, 2023
Due To Pavmed Inc.
Due To PAVmed Inc.	Note 5 — Due To PAVmed Inc. The aggregate Due To: PAVmed Inc. for the periods indicated is summarized as follows: Schedule of Due To: PAVmed Inc. MSA Fees Employee- Related Costs PAVmed Inc. OBO Payments Total Balance - December 31, 2022 $ 1,650 $ 3,026 $ 284 $ 4,960 MSA fees 6,750 — — 6,750 ERC - Payroll & Benefits — 1,382 — 1,382 On Behalf Of (OBO) activities — — 841 841 Cash payments to PAVmed Inc. (2,250 ) (309 ) (1,088 ) (3,647 ) Balance - September 30, 2023 $ 6,150 $ 4,099 $ 37 $ 10,286

Asset Purchase Agreement and Ma

Asset Purchase Agreement and Management Services Agreement	9 Months Ended
	Sep. 30, 2023
Asset Purchase Agreement And Management Services Agreement
Asset Purchase Agreement and Management Services Agreement	Note 6 — Asset Purchase Agreement and Management Services Agreement Asset Purchase Agreement and Management Services Agreement - ResearchDx Inc. Through its wholly-owned subsidiary, LucidDx Labs Inc. (“LucidDx Labs”), the Company entered into an asset purchase agreement (“APA”) dated February 25, 2022, with ResearchDx, Inc. (“RDx”), an unrelated third-party - “APA-RDx”. Under the APA-RDx, LucidDx Labs Inc. acquired certain assets from RDx which were combined with other property and equipment to establish a Company-owned CLIA certified, CAP accredited commercial clinical laboratory capable of performing the EsoGuard® Esophageal DNA assay, inclusive of DNA extraction, next generation sequencing (“NGS”) and specimen storage. Prior to February 25, 2022, RDx provided such laboratory services at its owned CLIA-certified, CAP-accredited clinical laboratory. In connection with the execution and delivery of the APA-RDx, LucidDx Labs Inc. and RDx entered into a separate management services agreement (“MSA-RDx”), dated and effective February 25, 2022, pursuant to which RDx provided certain testing and related services for the Laboratory. The total purchase price consideration payable under the APA-RDx is a face value of $ 3,200 3,200 Intangible Assets, net. Termination of Management Services Agreement and Modification of Other Payment Obligations - ResearchDx Inc. On February 14, 2023, through LucidDx Labs Inc, the Company entered into an agreement (the “MSA Termination Agreement”) with RDx, pursuant to which the parties mutually agreed to terminate the MSA-RDx without cause. The termination was effective as February 10, 2023. Until the termination of the management service agreement with RDx, RDx had continued to provide certain testing and related services for the Laboratory in accordance with the terms of the MSA-RDx. The MSA Termination Agreement reduces the remaining amounts of the earnout payments and management fees due under the APA-RDx and the MSA-RDx to $ 713 553,436

Prepaid Expenses, Deposits, and

Prepaid Expenses, Deposits, and Other Current Assets	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses Deposits And Other Current Assets
Prepaid Expenses, Deposits, and Other Current Assets	Note 7 — Prepaid Expenses, Deposits, and Other Current Assets Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets September 30, 2023 December 31, 2022 Advanced payments to service providers and suppliers $ 273 $ 371 Prepaid insurance 44 52 Deposits 2,725 1,331 EsoCheck cell collection supplies 190 59 EsoGuard mailer supplies — 52 Total prepaid expenses, deposits and other current assets $ 3,232 $ 1,865

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases
Leases	Note 8 — Leases During the nine months ended September 30, 2023, the Company entered into additional lease agreements that have commenced and are classified as operating leases and short-term leases for additional Lucid Test Centers. The Company’s future lease payments as of September 30, 2023, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule Of Future Lease Payments Of Operating Lease Liabilities 2023 (remainder of year) $ 313 2024 1,161 2025 127 2026 63 2027 24 Total lease payments $ 1,688 Less: imputed interest (96 ) Present value of lease liabilities $ 1,592 Note 8 — Leases Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule Of Cash Flow Supplemental Information Nine Months Ended September 30, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 894 $ 689 Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ 380 $ 2,567 Weighted-average remaining lease term - operating leases (in years) 1.58 2.24 Weighted-average discount rate - operating leases 7.875 % 7.875 % As of September 30, 2023 and December 31, 2022, the Company’s right-of-use assets from operating leases were $ 1,594 2,008 1,592 1,999 1,128 962 464 1,037

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Note 9 — Intangible Assets, net Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets Estimated Useful Life September 30, 2023 December 31, 2022 Defensive technology 60 $ 2,105 $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 3,200 $ 3,200 Total Intangible assets 5,305 5,305 Less Accumulated Amortization (3,376 ) (1,860 ) Intangible Assets, net $ 1,929 $ 3,445 The defensive technology intangible asset of $ 2.1 0.2 2.1 60 As noted in Note 6, Asset Purchase Agreement and Management Services Agreement Amortization expense of the intangible assets discussed above was $ 505 505 1,516 1,144 Schedule of Future Amortization Expense 2023 (remainder of year) $ 505 2024 688 2025 421 2026 315 Total $ 1,929

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 10 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the reporting date noted is as follows: Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurement on a Recurring Basis at Reporting Date Using 1 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total September 30, 2023 March 2023 Senior Convertible Note $ — $ — $ 14,490 $ 14,490 Totals $ — $ — $ 14,490 $ 14,490 1 There were no transfers between the respective Levels during the period ended September 30, 2023. As discussed in Note 11, Debt 11.1 The estimated fair value of the financial instruments classified within the Level 3 category was determined using both observable inputs and unobservable inputs. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs. The estimated fair value of the March 2023 Senior Convertible Note as of each of March 21, 2023 and September 30, 2023 were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption Used March 2023 Senior Convertible Note: March 2023 Senior Convertible Note: Fair Value $ 11,900 $ 14,490 Face value principal payable $ 11,111 $ 11,019 Required rate of return 11.00 % 11.10 % Conversion Price $ 5.00 $ 5.00 Value of common stock $ 1.54 $ 1.17 Expected term (years) 2.00 1.47 Volatility 75.00 % 65.00 % Risk free rate 4.09 % 5.13 % Dividend yield — % — % The estimated fair values reported utilized the Company’s common stock price along with certain Level 3 inputs (as discussed in the table above), in the development of Monte Carlo simulation models, discounted cash flow analyses, and /or Black-Scholes valuation models. The estimated fair values are subjective and are affected by changes in inputs to the valuation models and analyses, including the Company’s common stock price, the Company’s dividend yield, the risk-free rates based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in the value of the Company’s common stock price. Changes in these assumptions can materially affect the estimated fair values.

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	Note 11 — Debt The fair value and face value principal outstanding of the March 2023 Senior Convertible Note as of the dates indicated are as follows: Summary of Outstanding Debt Contractual Maturity Date Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 $ 11,019 $ 14,490 Balance as of September 30, 2023 $ 11,019 $ 14,490 The changes in the fair value of debt during the three and nine months ended September 30, 2023 is as follows: Schedule of Changes in Fair Value of Debt March 2023 Senior Convertible Note Other Income (expense) Fair Value - June 30, 2023 $ 11,610 $ — Face value principal – issue date Fair value adjustment – issue date Installment repayments – common stock (92 ) — Non-installment payments – common stock (49 ) — Change in fair value 3,021 (3,021 ) Fair Value at September 30, 2023 $ 14,490 - Other Income (Expense) - Change in fair value – three months ended September 30, 2023 $ (3,021 ) March 2023 Senior Convertible Note Other Income (expense) Fair Value - December 31, 2022 $ — $ — Fair Value - Beginning balance $ — $ — Face value principal – issue date 11,111 $ — Fair value adjustment – issue date 789 (789 ) Installment repayments – common stock (92 ) — Non-installment payments – common stock (49 ) — Change in fair value 2,731 (2,731 ) Fair Value at September 30, 2023 $ 14,490 - Fair Value - Ending balance $ 14,490 - Other Income (Expense) - Change in fair value – nine months ended September 30, 2023 $ (3,520 ) March 2023 Senior Secured Convertible Note Lucid Diagnostics entered into a Securities Purchase Agreement (“SPA”) dated March 13, 2023, with an accredited institutional investor (“Investor”, “Lender”, and /or “Holder”), wherein Lucid agreed to sell, and the Investor agreed to purchase, an aggregate of $ 11.1 Under the SPA, Lucid issued in a registered direct offering under its effective shelf registration statement a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “March 2023 Senior Convertible Note”, with such note having a $ 11.1 7.875 5.00 March 21, 2025 The March 2023 Senior Convertible Note proceeds were $ 9.925 1.186 During the period from March 21, 2023 to September 20, 2023, Lucid is required to pay interest expense only (on the $ 11.1 7.875 148 391 Note 11 — Debt Commencing September 21, 2023, and then on each of the successive first and tenth trading day of each month thereafter through to and including March 14, 2025 (each referred to as an “Installment Date”); and on the March 21, 2025 292 In addition to the Installment Amount repayments, the Holder may elect to accelerate the conversion of future Installment Amount repayments, and interest thereon, subject to certain restrictions, as defined, utilizing the then current conversion price of the most recent Installment Date conversion price. The payment of all amounts due and payable under this senior convertible note is guaranteed by all of Lucid Diagnostics’ subsidiaries; and the obligations under this senior convertible note are secured by all of the assets of Lucid Diagnostics and its subsidiaries. Lucid is subject to certain customary affirmative and negative covenants regarding the rank of the note, along with the incurrence of further indebtedness, the existence of liens, the repayment of indebtedness and the making of investments, the payment of cash in respect of dividends, distributions or redemptions, the transfer of assets, the maturity of other indebtedness, and transactions with affiliates, among other customary matters. Lucid is subject to financial covenants requiring: (i) a minimum of $5.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company’s average market capitalization over the prior ten trading days, as of the last day of any fiscal quarter commencing with September 30, 2023, to not exceed 30%; and (iii) the Company’s market capitalization to at no time be less than $30 million In the nine months ended September 30, 2023, approximately $ 92 48 115,388 166 26

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 12 — Stock-Based Compensation Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics 2018 Equity Plan”) is separate and apart from the PAVmed 2014 Equity Plan discussed below. The Lucid Diagnostics 2018 Equity Plan is designed to enable Lucid Diagnostics to offer employees, officers, directors, and consultants, an opportunity to acquire shares of common stock of Lucid Diagnostics. The types of awards that may be granted under the Lucid Diagnostics 2018 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics compensation committee. A total of 11,644,000 3,929,301 423,300 50,000 Note 12 — Stock-Based Compensation Lucid Diagnostics Stock Options Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Stock Options Issued and Outstanding Activities Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2022 2,565,377 $ 3.14 8.3 $ 428 Granted (1) 2,982,500 $ 1.32 Exercised — $ — Forfeited (590,662 ) $ 2.70 Outstanding stock options at September 30, 2023 (3) 4,957,215 $ 2.10 8.6 $ 347 Vested and exercisable stock options at September 30, 2023 1,439,442 $ 2.77 7.0 $ 347 (1) Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 30, 2023 and December 31, 2022 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above, are inclusive of 423,300 See Note 4, Related Party Transactions Subsequent to September 30, 2023, on November 6, 2023, the company granted to employees 500,000 with a weighted average exercise price of $ 1.29 Lucid Diagnostics Restricted Stock Awards Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2022 (1) 2,091,420 $ 11.44 Granted — — Vested (303,980 ) 11.95 Forfeited — — Unvested restricted stock awards as of September 30, 2023 1,787,440 $ 11.36 (1) The unvested restricted stock awards presented in the table above, are inclusive of 50,000 50,000 Subsequent to September 30, 2023, on November 6, 2023, 550,000 0.7 PAVmed Inc. 2014 Equity Plan The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the “PAVmed 2014 Equity Plan”), is separate and apart from the Lucid Diagnostics 2018 Equity Plan (as such equity plan is discussed above). Note 12 — Stock-Based Compensation Stock-Based Compensation Expense The stock-based compensation expense recognized by the Company for both the Lucid Diagnostics 2018 Equity Plan and the PAVmed 2014 Equity Plan, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Lucid Diagnostics 2018 Equity Plan – cost of revenue $ 16 $ 9 $ 44 $ 9 Lucid Diagnostics 2018 Equity Plan – sales and marketing 228 253 697 733 Lucid Diagnostics 2018 Equity Plan - general and administrative 721 2,990 4,069 9,504 Lucid Diagnostics 2018 Equity Plan - research and development 67 28 204 125 PAVmed 2014 Equity Plan - cost of revenue 10 — 26 — PAVmed 2014 Equity Plan - sales and marketing 106 161 359 497 PAVmed 2014 Equity Plan - general and administrative 7 78 170 224 PAVmed 2014 Equity Plan - research and development 97 52 290 159 Total stock-based compensation expense $ 1,252 $ 3,571 $ 5,859 $ 11,251 The stock-based compensation expense, as presented above, is inclusive of: stock options and restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan to employees of PAVmed, the Physician Inventors, and members of the board of directors of Lucid Diagnostics, as well as the stock options granted under the PAVmed 2014 Equity Plan to the Physician Inventors. As of September 30, 2023, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the Lucid Diagnostics 2018 Equity Plan and the PAVmed 2014 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period Unrecognized Expense Weighted Average Remaining Service Period (Years) Lucid Diagnostics 2018 Equity Plan Stock Options $ 3,620 2.1 Restricted Stock Awards $ 633 1.0 PAVmed 2014 Equity Plan Stock Options $ 608 1.9 Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $ 0.88 1.61 Schedule of Stock-based Compensation Valuation Assumptions 2023 2022 Nine Months Ended September 30, 2023 2022 Expected term of stock options (in years) 5.6 5.8 Expected stock price volatility 75 % 72 % Risk free interest rate 3.7 % 3.2 % Expected dividend yield — % — % Lucid Diagnostics Inc Employee Stock Purchase Plan (“Lucid ESPP”) A total of 231,987 276 276,213 84,030 275 109 1,000,000 407,770 500,000

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 13 — Stockholders’ Equity Series A Preferred Stock Offering On March 7, 2023, the Company issued 13,625 0.001 1,000 13.625 Each share of Series A Preferred Stock is convertible at the option of the holder, subject to certain beneficial ownership limitations into such number of shares of the Company’s common stock, equal to the number of Series A Preferred Shares to be converted, multiplied by the stated value of $ 1,000 1.394 The Series A Preferred Stock will be senior to the Common Stock and any other class of the Company’s capital stock that is not by its terms senior to or pari passu with the Series A Preferred Stock. The holders of Series A Preferred Stock will be entitled to dividends payable as follows: (i) a number of shares of Common Stock equal to 20% of the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock then held by such Holder on March 7, 2024, and (ii) a number of shares of Common Stock equal to 20% of the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock then held by such Holder on March 7, 2025. A holder that converts its Series A Preferred Stock prior to March 7, 2024 or March 7, 2025, as the case may be, will not receive the dividend that accrues on such date with respect to such converted Series A Preferred Stock. The holders of the Series A Preferred Stock also will be entitled to dividends equal, on an as-if-converted to shares of Common Stock basis, to and in the same form as dividends actually paid on shares of the Common Stock when, as, and if such dividends are paid on shares of the Common Stock In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (or any Deemed Liquidation Event as defined in the Certificate of Designation), the holders of shares of Series A Preferred Stock then outstanding will be entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the Stated Value, plus any dividends accrued but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Series A Preferred Stock been converted into Common Stock immediately prior to such event. The Series A Preferred Stock is a non-voting security, other than with respect to limited matters related to changes in terms of the Series A Preferred Stock. The Company will not effect any conversion of the Series A Preferred Stock, and a holder will not have the right to receive dividends or convert any portion of the Series A Preferred Stock, to the extent that, after giving effect to the receipt of dividends or the conversion, the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of the holder’s affiliates) would beneficially own in excess of 4.99% of the Company’s outstanding common stock (or, upon election of the holder, 9.99% of the Company’s outstanding common stock) The Company and the investors in the offering also executed a registration rights agreement (the “Series A Registration Rights Agreement”), pursuant to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable pursuant to the Series A Preferred Stock. Series A-1 Preferred Stock Offering Subsequent to September 30, 2023, on October 17, 2023, the Company issued 5,000 1.2592 5.0 The Company and the investors in the offering also executed a registration rights agreement (the “Series A-1 Registration Rights Agreement”), pursuant to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable pursuant to the Series A-1 Preferred Stock. Lucid Diagnostics Common Stock In June 2023, the Company received shareholder approval to issue up to 200 100 As of September 30, 2023 and December 31, 2022 there were 42,329,864 40,518,792 31,302,420 Note 13 — Stockholders’ Equity Committed Equity Facility and ATM Facility On March 28, 2022, the Company entered into a committed equity facility with an affiliate of Cantor Fitzgerald (“Cantor”). Under the terms of the committed equity facility, Cantor has committed to purchase up to $ 50 680,263 1.8 4 In November 2022, the Company entered into an “at-the-market offering” (“ATM”) for up to $ 6.5 230,068 0.3 3 No

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Note 14 — Net Loss Per Share The Net loss per share basic and diluted for the respective periods indicated is as follows: Schedule of Net Loss Per Share Basic and Diluted 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Numerator Net loss $ (14,208 ) $ (14,349 ) $ (41,836 ) $ (41,243 ) Denominator Weighted average common shares outstanding, basic and diluted 41,862,805 36,405,945 41,558,979 35,767,857 Net loss per share Net loss per share - basic and diluted $ (0.34 ) $ (0.39 ) $ (1.01 ) $ (1.15 ) Basic weighted-average number of shares of common stock outstanding for the periods ended September 30, 2023 and 2022 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: Schedule of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share 2023 2022 September 30, 2023 2022 Stock options 4,957,215 2,633,089 Unvested restricted stock awards 1,787,440 2,091,420 Preferred stock 13,683,647 — Total 20,428,302 4,724,509

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company is a majority-owned consolidated subsidiary of PAVmed, which has a majority equity ownership interest and has financial control of the Company. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2022 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company’s unaudited condensed consolidated financial information. The consolidated results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2023 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company’s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K as filed with the SEC on March 14, 2023. All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts.
Use of Estimates	Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserves, if any, and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards and intangible assets. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.
Revenue Recognition	Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Note 2 — Summary of Significant Accounting Policies The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Allocate transaction price Practical Expedients
Financial Instruments Fair Value Measurements	Financial Instruments Fair Value Measurements FASB ASC Topic 820, Fair Value Measurement, (ASC 820) defines fair value as the price which would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at a transaction measurement date. The ASC 820 three-tier fair value hierarchy prioritizes the inputs used in the valuation methodologies, as follows: Level Valuations based on quoted prices for identical assets and liabilities in active markets. Level Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets which are not active, or other inputs observable or can be corroborated by observable market data. Level 3 Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company evaluates its financial instruments to determine if those instruments or any embedded components of those instruments potentially qualify as derivatives required to be separately accounted for in accordance with FASB ASC Topic 815, Derivatives and Hedging (ASC 815). Note 2 — Summary of Significant Accounting Policies The recurring and non-recurring estimated fair value measurements are subjective and are affected by changes in inputs to the valuation models, including the Company’s common stock price, and certain Level 3 inputs, including, the assumptions regarding the estimated volatility in the value of the Company’s common stock price; the Company’s dividend yield; the likelihood and timing of future dilutive transactions, as applicable, along with the risk-free rates based on U.S. Treasury security yields. Changes in these assumptions can materially affect the estimated fair values. As of September 30, 2023 and December 31, 2022, the carrying values of cash, and accounts payable, approximate their respective fair value due to the short-term nature of these financial instruments.
Fair Value Option (“FVO”) Election	Fair Value Option (“FVO”) Election Under a Securities Purchase Agreement dated March 13, 2023, the Company issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “March 2023 Senior Convertible Note”, which is accounted under the “fair value option election” as discussed below. Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivative and Hedging Alternatively, FASB ASC Topic 825, Financial Instruments See Note 10, Financial Instruments Fair Value Measurements, with respect to the FVO election; and Note 11, Debt, for a discussion of the March 2023 Senior Convertible Note.
Reclassifications	Reclassifications Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The updated guidance requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets, including trade receivables. The guidance was adopted by the Company on January 1, 2023. The adoption of the ASU did not have an impact on the Company’s unaudited condensed consolidated financial statements.

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Schedule of Incurred Expenses of Minority Shareholders	Schedule of Incurred Expenses of Minority Shareholders 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of Revenue CWRU – Royalty Fees $ 42 $ 4 $ 76 $ 13 General and Administrative Expense Amended CWRU – License Agreement - reimbursement of patent legal fees 343 — 732 209 Stock-based compensation expense – Physician Inventors’ restricted stock awards — 275 180 819 Research and Development Expense Fees - Physician Inventors’ consulting agreements 5 15 15 32 Sponsored research agreement — 4 — 6 Stock-based compensation expense – Physician Inventors’ stock options 52 52 157 151 Total Related Party Expenses $ 442 $ 350 $ 1,160 $ 1,230
Schedule of MSA Fee Expense Classification in Statements of Operations	Schedule of MSA Fee Expense Classification in Statements of Operations 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Sales & Marketing 109 330 327 713 General & Administrative 1,621 891 4,729 2,175 Research & Development 520 429 1,694 1,102 Total MSA Fee $ 2,250 $ 1,650 $ 6,750 $ 3,990

Due To PAVmed Inc. (Tables)

Due To PAVmed Inc. (Tables)	9 Months Ended
	Sep. 30, 2023
Due To Pavmed Inc.
Schedule of Due To: PAVmed Inc.	The aggregate Due To: PAVmed Inc. for the periods indicated is summarized as follows: Schedule of Due To: PAVmed Inc. MSA Fees Employee- Related Costs PAVmed Inc. OBO Payments Total Balance - December 31, 2022 $ 1,650 $ 3,026 $ 284 $ 4,960 MSA fees 6,750 — — 6,750 ERC - Payroll & Benefits — 1,382 — 1,382 On Behalf Of (OBO) activities — — 841 841 Cash payments to PAVmed Inc. (2,250 ) (309 ) (1,088 ) (3,647 ) Balance - September 30, 2023 $ 6,150 $ 4,099 $ 37 $ 10,286

Prepaid Expenses, Deposits, a_2

Prepaid Expenses, Deposits, and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses Deposits And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets September 30, 2023 December 31, 2022 Advanced payments to service providers and suppliers $ 273 $ 371 Prepaid insurance 44 52 Deposits 2,725 1,331 EsoCheck cell collection supplies 190 59 EsoGuard mailer supplies — 52 Total prepaid expenses, deposits and other current assets $ 3,232 $ 1,865

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases
Schedule Of Future Lease Payments Of Operating Lease Liabilities	The Company’s future lease payments as of September 30, 2023, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule Of Future Lease Payments Of Operating Lease Liabilities 2023 (remainder of year) $ 313 2024 1,161 2025 127 2026 63 2027 24 Total lease payments $ 1,688 Less: imputed interest (96 ) Present value of lease liabilities $ 1,592
Schedule Of Cash Flow Supplemental Information	Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule Of Cash Flow Supplemental Information Nine Months Ended September 30, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 894 $ 689 Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ 380 $ 2,567 Weighted-average remaining lease term - operating leases (in years) 1.58 2.24 Weighted-average discount rate - operating leases 7.875 % 7.875 %

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets Estimated Useful Life September 30, 2023 December 31, 2022 Defensive technology 60 $ 2,105 $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 3,200 $ 3,200 Total Intangible assets 5,305 5,305 Less Accumulated Amortization (3,376 ) (1,860 ) Intangible Assets, net $ 1,929 $ 3,445
Schedule of Future Amortization Expense	Schedule of Future Amortization Expense 2023 (remainder of year) $ 505 2024 688 2025 421 2026 315 Total $ 1,929

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis	The fair value hierarchy table for the reporting date noted is as follows: Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurement on a Recurring Basis at Reporting Date Using 1 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total September 30, 2023 March 2023 Senior Convertible Note $ — $ — $ 14,490 $ 14,490 Totals $ — $ — $ 14,490 $ 14,490 1 There were no transfers between the respective Levels during the period ended September 30, 2023.
Schedule of Fair Value Assumption Used	The estimated fair value of the March 2023 Senior Convertible Note as of each of March 21, 2023 and September 30, 2023 were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption Used March 2023 Senior Convertible Note: March 2023 Senior Convertible Note: Fair Value $ 11,900 $ 14,490 Face value principal payable $ 11,111 $ 11,019 Required rate of return 11.00 % 11.10 % Conversion Price $ 5.00 $ 5.00 Value of common stock $ 1.54 $ 1.17 Expected term (years) 2.00 1.47 Volatility 75.00 % 65.00 % Risk free rate 4.09 % 5.13 % Dividend yield — % — %

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Summary of Outstanding Debt	The fair value and face value principal outstanding of the March 2023 Senior Convertible Note as of the dates indicated are as follows: Summary of Outstanding Debt Contractual Maturity Date Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 $ 11,019 $ 14,490 Balance as of September 30, 2023 $ 11,019 $ 14,490
Schedule of Changes in Fair Value of Debt	The changes in the fair value of debt during the three and nine months ended September 30, 2023 is as follows: Schedule of Changes in Fair Value of Debt March 2023 Senior Convertible Note Other Income (expense) Fair Value - June 30, 2023 $ 11,610 $ — Face value principal – issue date Fair value adjustment – issue date Installment repayments – common stock (92 ) — Non-installment payments – common stock (49 ) — Change in fair value 3,021 (3,021 ) Fair Value at September 30, 2023 $ 14,490 - Other Income (Expense) - Change in fair value – three months ended September 30, 2023 $ (3,021 ) March 2023 Senior Convertible Note Other Income (expense) Fair Value - December 31, 2022 $ — $ — Fair Value - Beginning balance $ — $ — Face value principal – issue date 11,111 $ — Fair value adjustment – issue date 789 (789 ) Installment repayments – common stock (92 ) — Non-installment payments – common stock (49 ) — Change in fair value 2,731 (2,731 ) Fair Value at September 30, 2023 $ 14,490 - Fair Value - Ending balance $ 14,490 - Other Income (Expense) - Change in fair value – nine months ended September 30, 2023 $ (3,520 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Options Issued and Outstanding Activities	Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Stock Options Issued and Outstanding Activities Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2022 2,565,377 $ 3.14 8.3 $ 428 Granted (1) 2,982,500 $ 1.32 Exercised — $ — Forfeited (590,662 ) $ 2.70 Outstanding stock options at September 30, 2023 (3) 4,957,215 $ 2.10 8.6 $ 347 Vested and exercisable stock options at September 30, 2023 1,439,442 $ 2.77 7.0 $ 347 (1) Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 30, 2023 and December 31, 2022 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above, are inclusive of 423,300
Schedule of Restricted Stock Award Activity	Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2022 (1) 2,091,420 $ 11.44 Granted — — Vested (303,980 ) 11.95 Forfeited — — Unvested restricted stock awards as of September 30, 2023 1,787,440 $ 11.36 (1) The unvested restricted stock awards presented in the table above, are inclusive of 50,000 50,000
Schedule of Stock-Based Compensation Expense	The stock-based compensation expense recognized by the Company for both the Lucid Diagnostics 2018 Equity Plan and the PAVmed 2014 Equity Plan, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Lucid Diagnostics 2018 Equity Plan – cost of revenue $ 16 $ 9 $ 44 $ 9 Lucid Diagnostics 2018 Equity Plan – sales and marketing 228 253 697 733 Lucid Diagnostics 2018 Equity Plan - general and administrative 721 2,990 4,069 9,504 Lucid Diagnostics 2018 Equity Plan - research and development 67 28 204 125 PAVmed 2014 Equity Plan - cost of revenue 10 — 26 — PAVmed 2014 Equity Plan - sales and marketing 106 161 359 497 PAVmed 2014 Equity Plan - general and administrative 7 78 170 224 PAVmed 2014 Equity Plan - research and development 97 52 290 159 Total stock-based compensation expense $ 1,252 $ 3,571 $ 5,859 $ 11,251
Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period	As of September 30, 2023, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the Lucid Diagnostics 2018 Equity Plan and the PAVmed 2014 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period Unrecognized Expense Weighted Average Remaining Service Period (Years) Lucid Diagnostics 2018 Equity Plan Stock Options $ 3,620 2.1 Restricted Stock Awards $ 633 1.0 PAVmed 2014 Equity Plan Stock Options $ 608 1.9
Schedule of Stock-based Compensation Valuation Assumptions	Schedule of Stock-based Compensation Valuation Assumptions 2023 2022 Nine Months Ended September 30, 2023 2022 Expected term of stock options (in years) 5.6 5.8 Expected stock price volatility 75 % 72 % Risk free interest rate 3.7 % 3.2 % Expected dividend yield — % — %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share Basic and Diluted	The Net loss per share basic and diluted for the respective periods indicated is as follows: Schedule of Net Loss Per Share Basic and Diluted 2023 2022 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Numerator Net loss $ (14,208 ) $ (14,349 ) $ (41,836 ) $ (41,243 ) Denominator Weighted average common shares outstanding, basic and diluted 41,862,805 36,405,945 41,558,979 35,767,857 Net loss per share Net loss per share - basic and diluted $ (0.34 ) $ (0.39 ) $ (1.01 ) $ (1.15 )
Schedule of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share	Schedule of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share 2023 2022 September 30, 2023 2022 Stock options 4,957,215 2,633,089 Unvested restricted stock awards 1,787,440 2,091,420 Preferred stock 13,683,647 — Total 20,428,302 4,724,509

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Details Narrative) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended		9 Months Ended
	Feb. 25, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from contract with customer		$ 783	$ 76	$ 1,388	$ 265
Cost of revenue		$ 1,634	$ 1,626	$ 4,522	$ 1,996
EsoGuard Commercialization Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum fixed monthly fee	$ 100

Schedule of Incurred Expenses o

Schedule of Incurred Expenses of Minority Shareholders (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total Related Party Expenses	$ 442	$ 350	$ 1,160	$ 1,230
Cost of Revenue [Member]
CWRU – Royalty Fees	42	4	76	13
General and Administrative Expense [Member]
Amended CWRU – License Agreement - reimbursement of patent legal fees	343		732	209
Stock-based compensation expense – Physician Inventors’ restricted stock awards		275	180	819
Research and Development Expense [Member]
Fees - Physician Inventors’ consulting agreements	5	15	15	32
Sponsored research agreement		4		6
Stock-based compensation expense – Physician Inventors’ stock options	$ 52	$ 52	$ 157	$ 151

Schedule of MSA Fee Expense Cla

Schedule of MSA Fee Expense Classification in Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Related Party Transaction [Line Items]
Total MSA Fee			$ 6,750
Pavmed Inc [Member] | Management Services Agreement [Member]
Related Party Transaction [Line Items]
Total MSA Fee	$ 2,250	$ 1,650	6,750	$ 3,990
Pavmed Inc [Member] | Management Services Agreement [Member] | Selling and Marketing Expense [Member]
Related Party Transaction [Line Items]
Total MSA Fee	109	330	327	713
Pavmed Inc [Member] | Management Services Agreement [Member] | General and Administrative Expense [Member]
Related Party Transaction [Line Items]
Total MSA Fee	1,621	891	4,729	2,175
Pavmed Inc [Member] | Management Services Agreement [Member] | Research and Development Expense [Member]
Related Party Transaction [Line Items]
Total MSA Fee	$ 520	$ 429	$ 1,694	$ 1,102

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	Jan. 01, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Outstanding payable				$ 10,286	$ 4,960
Related Party [Member]
Related Party Transaction [Line Items]
Outstanding payable				$ 820
Pavmed Inc [Member]
Related Party Transaction [Line Items]
MSA fees per month	$ 750	$ 550	$ 390

Schedule of Due To_ PAVmed Inc.

Schedule of Due To: PAVmed Inc. (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Short-Term Debt [Line Items]
Balance - December 31, 2022	$ 4,960
MSA fees	6,750
ERC - Payroll & Benefits	1,382
On Behalf Of (OBO) activities	841
Cash payments to PAVmed Inc.	(3,647)
Balance - September 30, 2023	10,286
MSA Fees [Member]
Short-Term Debt [Line Items]
Balance - December 31, 2022	1,650
MSA fees	6,750
ERC - Payroll & Benefits
On Behalf Of (OBO) activities
Cash payments to PAVmed Inc.	(2,250)
Balance - September 30, 2023	6,150
ERC Payroll Benefits [Member]
Short-Term Debt [Line Items]
Balance - December 31, 2022	3,026
MSA fees
ERC - Payroll & Benefits	1,382
On Behalf Of (OBO) activities
Cash payments to PAVmed Inc.	(309)
Balance - September 30, 2023	4,099
OBO Payments [Member]
Short-Term Debt [Line Items]
Balance - December 31, 2022	284
MSA fees
ERC - Payroll & Benefits
On Behalf Of (OBO) activities	841
Cash payments to PAVmed Inc.	(1,088)
Balance - September 30, 2023	$ 37

Asset Purchase Agreement and _2

Asset Purchase Agreement and Management Services Agreement (Details Narrative) - USD ($) $ in Thousands		1 Months Ended
	Feb. 25, 2022	Feb. 28, 2023	Feb. 14, 2023
MSA Termination Agreement [Member]
Asset Acquisition [Line Items]
Earnout payments and management fees due			$ 713
Issuance of common shares		553,436
Research DX Inc [Member] | Asset Purchase Agreement [Member]
Asset Acquisition [Line Items]
Purchase price consideration payable	$ 3,200
Intangible assets	$ 3,200

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expenses Deposits And Other Current Assets
Advanced payments to service providers and suppliers	$ 273	$ 371
Prepaid insurance	44	52
Deposits	2,725	1,331
EsoCheck cell collection supplies	190	59
EsoGuard mailer supplies		52
Total prepaid expenses, deposits and other current assets	$ 3,232	$ 1,865

Schedule Of Future Lease Paymen

Schedule Of Future Lease Payments Of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases
2023 (remainder of year)	$ 313
2024	1,161
2025	127
2026	63
2027	24
Total lease payments	1,688
Less: imputed interest	(96)
Present value of lease liabilities	$ 1,592	$ 1,999

Schedule Of Cash Flow Supplemen

Schedule Of Cash Flow Supplemental Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Leases
Operating cash flows from operating leases	$ 894	$ 689
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 380	$ 2,567
Weighted-average remaining lease term - operating leases (in years)	1 year 6 months 29 days	2 years 2 months 26 days
Weighted-average discount rate - operating leases	7.875%	7.875%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases
Operating lease right of use asset	$ 1,594	$ 2,008
Operating lease obligations	1,592	1,999
Operating lease liabilities, current	1,128	962
Operating lease liabilities, non-current	$ 464	$ 1,037

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Total Intangible assets	$ 5,305	$ 5,305
Less Accumulated Amortization	(3,376)	(1,860)
Total Intangible Assets, net	$ 1,929	$ 3,445
Defensive Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	60 months	60 months
Total Intangible assets	$ 2,105	$ 2,105
Laboratory Information Management Software [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	24 months	24 months
Total Intangible assets	$ 3,200	$ 3,200

Schedule of Future Amortization

Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (remainder of year)	$ 505
2024	688
2025	421
2026	315
Total	$ 1,929	$ 3,445

Intangible Assets, net (Details

Intangible Assets, net (Details Narrative) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Oct. 05, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Apr. 01, 2022
Impairment Effects on Earnings Per Share [Line Items]
Intangible assets		$ 5,305		$ 5,305		$ 5,305
Accumulated amortization		(3,376)		(3,376)		$ (1,860)
Amortization expense of intangible assets		$ 505	$ 505	$ 1,516	$ 1,144
Defensive Technology [Member]
Impairment Effects on Earnings Per Share [Line Items]
Intangible assets							$ 2,100
Accumulated amortization							$ 200
Defensive Technology [Member] | Pavmed Inc [Member]
Impairment Effects on Earnings Per Share [Line Items]
Purchase consideration paid	$ 2,100
Finite lived intangible asset useful life	60 months

Schedule of Financial Liabiliti

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) $ in Thousands	Sep. 30, 2023 USD ($)	[1]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	$ 14,490
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	14,490
March 2023 Senior Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	14,490
March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability
March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability
March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	$ 14,490
[1]There were no transfers between the respective Levels during the period ended September 30, 2023.

Schedule of Fair Value Assumpti

Schedule of Fair Value Assumption Used (Details) $ in Thousands		9 Months Ended
	Mar. 21, 2023 USD ($) $ / shares	Sep. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Mar. 13, 2023 USD ($)	Dec. 31, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value		$ 14,490
Face value principal payable		11,019
March 2023 Senior Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 11,900	14,490	$ 11,610
Face value principal payable	$ 11,111	$ 11,019		$ 11,100
March 2023 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	11	11.10
March 2023 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input | $ / shares	5	5
March 2023 Senior Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input | $ / shares	1.54	1.17
March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years	2 years	1 year 5 months 19 days
March 2023 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	75	65
March 2023 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	4.09	5.13
March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 21, 2023	Mar. 13, 2023
Short-Term Debt [Line Items]
Face value principal payable	$ 11,019
March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable	$ 11,019	$ 11,111	$ 11,100

Summary of Outstanding Debt (De

Summary of Outstanding Debt (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Mar. 21, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 13, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Face Value Principal Outstanding		$ 11,019
Fair Value		$ 14,490
March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Contractual Maturity Date	Mar. 21, 2025	Mar. 21, 2025
Stated Interest Rate	7.875%	7.875%
Conversion Price	$ 5	$ 5
Face Value Principal Outstanding	$ 11,111	$ 11,019		$ 11,100
Fair Value	$ 11,900	$ 14,490	$ 11,610

Schedule of Changes in Fair Val

Schedule of Changes in Fair Value of Debt (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Fair Value - Ending balance	$ 14,490		$ 14,490
Other Income (Expense) - Change in fair value	3,021		3,520
Other Operating Income (Expense) [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning balance
Face value principal – issue date
Fair value adjustment – issue date			(789)
Installment repayments – common stock
Non-installment payments – common stock
Change in fair value	(3,021)		(2,731)
Fair Value - Ending balance
Other Income (Expense) - Change in fair value	(3,021)		(3,520)
March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning balance	11,610
Face value principal – issue date			11,111
Fair value adjustment – issue date			789
Installment repayments – common stock	(92)		(92)
Non-installment payments – common stock	(49)		(49)
Change in fair value	3,021		2,731
Fair Value - Ending balance	$ 14,490		$ 14,490

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended
	Sep. 21, 2023	Mar. 21, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 13, 2023
Short-Term Debt [Line Items]
Face value principal payable			$ 11,019		$ 11,019
Proceeds from convertible debt					10,000
Debt extinguishment loss			26		26
March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable		$ 11,111	$ 11,019		$ 11,019		$ 11,100
Stated interest rate		7.875%	7.875%		7.875%
Conversion price		$ 5	$ 5		$ 5
Debt instrument maturity date		Mar. 21, 2025			Mar. 21, 2025
Proceeds from convertible debt		$ 9,925
Debt fees amount		$ 1,186
Interest expense			$ 148		$ 391
Principal repayment	$ 292
Covenant description					(i) a minimum of $5.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company’s average market capitalization over the prior ten trading days, as of the last day of any fiscal quarter commencing with September 30, 2023, to not exceed 30%; and (iii) the Company’s market capitalization to at no time be less than $30 million
Debt principal repayments					$ 92
Interest paid					$ 48
Debt conversion, shares issued					115,388
Debt conversion, fair value of shares issued					$ 166
Debt extinguishment loss					$ 26

Schedule of Stock Options Issue

Schedule of Stock Options Issued and Outstanding Activities (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended		12 Months Ended
		Sep. 30, 2023		Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Number of Stock Options Outstanding, Beginning		2,565,377
Weighted Average Exercise Price, Beginning		$ 3.14
Remaining Contractual Term (Years)		8 years 7 months 6 days	[1]	8 years 3 months 18 days
Intrinsic Value, Beginning	[2]	$ 428
Number of Stock Options, Granted	[3]	2,982,500
Weighted Average Exercise Price, Granted	[3]	$ 1.32
Number of Stock Options, Exercised
Weighted Average Exercise Price, Exercised
Number of Stock Options, Forfeited		(590,662)
Weighted Average Exercise Price, Forfeited		$ 2.70
Number of Stock Options Outstanding, Ending		4,957,215	[1]	2,565,377
Weighted Average Exercise Price, Ending		$ 2.10	[1]	$ 3.14
Intrinsic Value, Ending	[2]	$ 347	[1]	$ 428
Number of Stock Options, Vested and exercisable		1,439,442
Weighted Average Exercise Price, Vested and exercisable stock options		$ 2.77
Remaining Contractual Term (Years), Vested and Exercisable		7 years
Intrinsic Value, Vested and exercisable	[2]	$ 347
[1]The outstanding stock options presented in the table above, are inclusive of 423,300

Schedule of Stock Options Iss_2

Schedule of Stock Options Issued and Outstanding Activities (Details) (Paranthetical) - shares		9 Months Ended	12 Months Ended
		Sep. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option grants	[1]	2,982,500
Outside of 2018 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option grants		423,300	423,300
[1]Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.

Schedule of Restricted Stock Aw

Schedule of Restricted Stock Award Activity (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Awards, Outstanding Beginning | shares	2,091,420	[1]
Weighted Average Grant Date Fair Value, Outstanding Beginning | $ / shares	$ 11.44	[1]
Number of Restricted Stock Awards, Granted | shares
Weighted Average Grant Date Fair Value, Granted | $ / shares
Number of Restricted Stock Awards, Vested | shares	(303,980)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 11.95
Number of Restricted Stock Awards, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Restricted Stock Awards, Outstanding Ending | shares	1,787,440
Weighted Average Grant Date Fair Value, Outstanding Ending | $ / shares	$ 11.36
[1]The unvested restricted stock awards presented in the table above, are inclusive of 50,000 50,000

Schedule of Restricted Stock _2

Schedule of Restricted Stock Award Activity (Details) (Paranthetical) - Restricted Stock [Member] - shares	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock awards, unvested	1,787,440	2,091,420	[1]
Number of restricted stock awards, vested	303,980
Outside of 2018 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock awards, unvested		50,000
Number of restricted stock awards, vested	50,000
[1]The unvested restricted stock awards presented in the table above, are inclusive of 50,000 50,000

Schedule of Stock-Based Compens

Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,252	$ 3,571	$ 5,859	$ 11,251
2018 Equity Plan [Member] | Cost of Revenue [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	16	9	44	9
2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	228	253	697	733
2018 Equity Plan [Member] | General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	721	2,990	4,069	9,504
2018 Equity Plan [Member] | Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	67	28	204	125
PAVmed Inc 2014 Equity Plan [Member] | Cost of Revenue [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	10		26
PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	106	161	359	497
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	7	78	170	224
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	$ 97	$ 52	$ 290	$ 159

Schedule of Unrecognized Compen

Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Share-Based Payment Arrangement, Option [Member] | 2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 3,620
Weighted Average Remaining Service Period (Years)	2 years 1 month 6 days
Share-Based Payment Arrangement, Option [Member] | PAVmed Inc 2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 608
Weighted Average Remaining Service Period (Years)	1 year 10 months 24 days
Restricted Stock [Member] | 2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 633
Weighted Average Remaining Service Period (Years)	1 year

Schedule of Stock-based Compe_2

Schedule of Stock-based Compensation Valuation Assumptions (Details) - 2018 Equity Plan [Member]	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 7 months 6 days	5 years 9 months 18 days
Expected stock price volatility	75%	72%
Risk free interest rate	3.70%	3.20%
Expected dividend yield

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
		Nov. 06, 2023	Jan. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option grants	[1]						2,982,500
Purchase - employee stock purchase plan, value				$ 275		$ 109	$ 551	$ 109
Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock awards, granted		550,000
Aggregate grant date fair value, vested		$ 700
Subsequent Event [Member] | Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options granted		500,000
Weighted average exercise price		$ 1.29
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock awards granted
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares reserved				11,644,000			11,644,000
Shares available for issue				3,929,301			3,929,301
2018 Equity Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average estimated fair value							$ 0.88	$ 1.61
Outside of 2018 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option grants							423,300		423,300
Outside of 2018 Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock awards granted							50,000
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares reserved				1,000,000			1,000,000
Shares available for issue				407,770			407,770
Purchase - employee stock purchase plan, shares				276,213	231,987	84,030
Purchase - employee stock purchase plan, value				$ 275	$ 276	$ 109
Increase in number of shares available-for-issue			500,000
[1]Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended	9 Months Ended
	Oct. 17, 2023	Mar. 07, 2023	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Nov. 30, 2022	Mar. 28, 2022
Class of Stock [Line Items]
Preferred stock, per share				$ 0.001	$ 0.001		$ 0.001
Preferred stock, stated value				$ 13,625,000	$ 13,625,000
Common stock, shares authorized			200,000,000	200,000,000	200,000,000		200,000,000
Increase in common stock authorized			100,000,000
Common stock, shares issued				42,329,864	42,329,864		40,518,792
Common stock, shares outstanding				42,329,864	42,329,864		40,518,792
Proceeds from issuance of common stock						$ 1,807,000
Proceeds from issuance of shares in ATM offering					$ 284,000
Cantor Fitzgerald [Member] | Commited Equity Facility [Member]
Class of Stock [Line Items]
Common stock authorized for sale									$ 50,000,000
Issuance of common stock					680,263
Proceeds from issuance of common stock					$ 1,800,000
Percentage of discount on sale of stock					4%
Cantor Fitzgerald [Member] | Controlled Equity Offering Agreement [Member]
Class of Stock [Line Items]
Common stock authorized for sale								$ 6,500,000
Number of shares issued in ATM offering				0	230,068
Proceeds from issuance of shares in ATM offering					$ 300,000
Percentage of commission paid to broker					3%
Pavmed Inc [Member]
Class of Stock [Line Items]
Majority-interest equity ownership shares				31,302,420	31,302,420
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued		13,625		13,625	13,625		0
Preferred stock, per share		$ 0.001
Share price, per share		$ 1,000
Proceeds from issuance of convertible preferred stock		$ 13,625,000
Preferred stock, stated value		$ 1,000
Preferred stock, conversion price per share		$ 1.394
Preferred stock dividend payment terms		The holders of Series A Preferred Stock will be entitled to dividends payable as follows: (i) a number of shares of Common Stock equal to 20% of the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock then held by such Holder on March 7, 2024, and (ii) a number of shares of Common Stock equal to 20% of the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock then held by such Holder on March 7, 2025. A holder that converts its Series A Preferred Stock prior to March 7, 2024 or March 7, 2025, as the case may be, will not receive the dividend that accrues on such date with respect to such converted Series A Preferred Stock. The holders of the Series A Preferred Stock also will be entitled to dividends equal, on an as-if-converted to shares of Common Stock basis, to and in the same form as dividends actually paid on shares of the Common Stock when, as, and if such dividends are paid on shares of the Common Stock
Conversion of stock, description		The Company will not effect any conversion of the Series A Preferred Stock, and a holder will not have the right to receive dividends or convert any portion of the Series A Preferred Stock, to the extent that, after giving effect to the receipt of dividends or the conversion, the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of the holder’s affiliates) would beneficially own in excess of 4.99% of the Company’s outstanding common stock (or, upon election of the holder, 9.99% of the Company’s outstanding common stock)
Series A-1 Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	5,000
Proceeds from issuance of convertible preferred stock	$ 5,000,000
Preferred stock, conversion price per share	$ 1.2592

Schedule of Net Loss Per Share

Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Net loss	$ (14,208)	$ (14,349)	$ (41,836)	$ (41,243)
Weighted average common shares outstanding, basic	41,862,805	36,405,945	41,558,979	35,767,857
Weighted average common shares outstanding, diluted	41,862,805	36,405,945	41,558,979	35,767,857
Net loss per common share - basic	$ (0.34)	$ (0.39)	$ (1.01)	$ (1.15)
Net loss per common share - diluted	$ (0.34)	$ (0.39)	$ (1.01)	$ (1.15)

Schedule of Common Stock Equiva

Schedule of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	20,428,302	4,724,509
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,957,215	2,633,089
Unvested Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,787,440	2,091,420
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	13,683,647